Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27404495 | 0.90 | ESR2 (0.50) | ESR2NR1H2HPGDUSP2SMN1; SMN2 | |
| SCHEMBL30800944 | 0.88 | ESR2 (0.45) | ESR2NR1H2HPGDUSP2SMN1; SMN2 | |
| SCHEMBL19341961 | 0.88 | ESR2 (0.45) | ESR2NR1H2HPGDUSP2SMN1; SMN2 | |
| SCHEMBL7884848 | 0.82 | KMT2A (0.48) | ESR2NR1H2HPGDUSP2SMN1; SMN2 | |
| SCHEMBL3748000 | 0.79 | ESR2 (0.48) | ESR2NR1H2HPGDUSP2SMN1; SMN2 | |
| SCHEMBL13160 | 0.79 | ESR2 (0.48) | ESR2NR1H2HPGDUSP2SMN1; SMN2 | |
| SCHEMBL14408022 | 0.78 | HPGD (0.47) | ESR2NR1H2HPGDUSP2SMN1; SMN2 | |
| SCHEMBL14415217 | 0.78 | HPGD (0.47) | ESR2NR1H2HPGDUSP2SMN1; SMN2 | |
| SCHEMBL893656 | 0.78 | ESR2 (0.47) | ESR2NR1H2HPGDUSP2SMN1; SMN2 | |
| SCHEMBL9426285 | 0.78 | ESR2 (0.50) | ESR2NR1H2HPGDUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150376193-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-31 | — | — | US | disclosed |
| US-9156847-B2 | Processes and intermediates for preparing a medicament | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-13 | — | — | US | disclosed |
| US-20140275126-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376193-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT | BTK, SYK, JAK2 | ESR2 3490/4885NR1H2 2404/4885HPGD 3244/4885 |
| US-20140275126-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT | BTK, SYK, JAK2 | ESR2 3490/4885NR1H2 2404/4885HPGD 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.